Stockholm - Delayed Quote ? SEK FluoGuide A/S (FLUO.ST) Follow Compare 35.60 +0.25 (+0.71%) At close: November 6 at 3:43 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer K?BENHAVN, DK / ACCESSWIRE / October 07, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biothech company specializing in precision cancer surgery, today announced the submission of the Clinical ... ACCESSWIRE ? 30 days ago FLUO.ST +0.71% FluoGuide A/S Publishes Interim Report for the Period January - March 2024 K?BENHAVN, DK / ACCESSWIRE / May 30, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 30 May 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2024. The Q1 report is available as ... ACCESSWIRE ? 5 months ago FLUO.ST +0.71% FluoGuide Selects Laser System for Photothermal Cancer Therapy with FG001 COPENHAGEN, DENMARK / ACCESSWIRE / May 27, 2024 /FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, has chosen laser system for the development of ... ACCESSWIRE ? 5 months ago FLUO.ST +0.71% Minutes from Annual General Meeting in FluoGuide A/S COPENHAGEN, DENMARK / ACCESSWIRE / March 20, 2024 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") held its annual general meeting on 20 March 2024. To the shareholders of FluoGuide A/S The Annual General Meeting was held Wednesday 20 March ... ACCESSWIRE ? 7 months ago FLUO.ST +0.71% Chief Financial Officer (CFO) Ole Larsen Buys Shares K?BENHAVN, DK / ACCESSWIRE / March 13, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - 13 March 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today announces that Ole Larsen (CFO) has bought shares. Member of the Executive Management Ole ... ACCESSWIRE ? 7 months ago FLUO.ST +0.71% FluoGuide Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001 K?BENHAVN, DENMARK / ACCESSWIRE / January 8, 2024 / FluoGuide A/S (STO:FLUO) Strong phase II data on FG001 in three indications: brain, head & neck, lung cancers Assessing potential of photothermal therapy in aggressive brain cancer Clinical trial ... ACCESSWIRE ? 9 months ago FLUO.ST +0.71% FluoGuide Raises SEK 12 million through Exercise of Warrants K?BENHAVN, DK / ACCESSWIRE / December 08, 2023 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a pioneer in the cutting-edge field of precision cancer surgery, today announced the status of the exercised ... ACCESSWIRE ? 10 months ago FLUO.ST +0.71% FluoGuide A/S Publishes Interim Report for the Period January - September 2023 K?BENHAVN, DENMARK / ACCESSWIRE / November 29, 2023 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 29 November 2023 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 September 2023. The Q3 report ... ACCESSWIRE ? 11 months ago FLUO.ST +0.71% FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference Oral presentation outlines positive efficacy and safety dataConfirms interim data showing FG001 met primary endpoint, with cancer lit up in 16 /16 (100%) patients, and was very well toleratedSeveral applications for potential clinical benefit will ... ACCESSWIRE ? 11 months ago FLUO.ST +0.71% FluoGuide Announces FG001 Meets Primary Endpoint in Phase llb Trial in Aggressive Brain Cancer All patients (12/12) receiving FG001 had additional cancer detected by optical guidanceFG001 was safe and well tolerated in all patientsK?BENHAVN, DENMARK / ACCESSWIRE / November 13, 2023 / FluoGuide A/S (STO:FLUO) FluoGuide A/S ("FluoGuide" or the ... ACCESSWIRE ? 11 months ago FLUO.ST +0.71% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return FLUO.ST OMX Stockholm 30 Index YTD -41.83% +6.46% 1-Year -59.17% +20.05% 3-Year -59.68% +9.82%
